IMMX vs CASI โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IMMX Captures Institutional Edge (2โ1 Pillars ยท 8โ0 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immix Biopharma, Inc. Common Stock (IMMX) driven by superior Growth & Margin, Momentum & Technical while CASI counters with relative strength in Options & Structure. Fundamentally, IMMX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CASI at N/M Forward P/E and -333.1% operating margin (-60.5% YoY). In options structure, IMMX sits in BREAKDOWN (30th %ile IV; Dealer Gamma Walls on Pro) against CASI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IMMX | CASI | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $590.0M | $12.4M | Larger Scale | IMMX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -60.5% | Higher Growth | IMMX |
| Operating Margin (TTM) Profitability | 0.0% | -333.1% | Higher Margin | IMMX |
| Net Profit Margin Profitability | 0.0% | -184.0% | Higher Margin | IMMX |
| Return on Equity (ROE) Capital Efficiency | -27.0% | -1094.5% | Higher ROE | IMMX |
| 52-Week Range Position Momentum | 28% ($4โ$15) | 0% ($0โ$3) | Stronger Trend | IMMX |
| Beta / 30D Volatility Risk Regime | 1.65ฮฒ ยท 76% Vol | 0.95ฮฒ ยท 240% Vol | Lower Realized Risk | IMMX |
| Unified Institutional Score Composite Signal | 50.6 / 100 (HOLD) | 44.7 / 100 (HOLD) | Higher Composite | IMMX |